Lyon Cuts TIGERMED Target Price to HK$58.9, Downgrades Earnings Forecasts

Stock News

Sep 01

Lyon released a research report stating that TIGERMED's (03347) second-quarter revenue declined 0.7% year-on-year to RMB 1.7 billion. New orders in the second quarter and July-August period both maintained double-digit growth, which aligns with the group's full-year order targets. The firm has reduced its revenue forecasts for TIGERMED for this year, next year, and 2027 by 6% across all periods, while earnings forecasts have been cut by 5% to 12%. The target price has been lowered from HK$62.6 to HK$58.9, while maintaining an "Outperform" rating.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1101208731"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1101208731\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1101208731?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-01 17:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1101208731","market":"nz","top_or_hot":-1,"title":"Lyon Cuts TIGERMED Target Price to HK$58.9, Downgrades Earnings Forecasts","media":"Stock News","content":"<p>Lyon released a research report stating that TIGERMED's (03347) second-quarter revenue declined 0.7% year-on-year to RMB 1.7 billion. New orders in the second quarter and July-August period both maintained double-digit growth, which aligns with the group's full-year order targets. The firm has reduced its revenue forecasts for TIGERMED for this year, next year, and 2027 by 6% across all periods, while earnings forecasts have been cut by 5% to 12%. The target price has been lowered from HK$62.6 to HK$58.9, while maintaining an \"Outperform\" rating.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lyon Cuts TIGERMED Target Price to HK$58.9, Downgrades Earnings Forecasts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLyon Cuts TIGERMED Target Price to HK$58.9, Downgrades Earnings Forecasts\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-01 17:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Lyon released a research report stating that TIGERMED's (03347) second-quarter revenue declined 0.7% year-on-year to RMB 1.7 billion. New orders in the second quarter and July-August period both maintained double-digit growth, which aligns with the group's full-year order targets. The firm has reduced its revenue forecasts for TIGERMED for this year, next year, and 2027 by 6% across all periods, while earnings forecasts have been cut by 5% to 12%. The target price has been lowered from HK$62.6 to HK$58.9, while maintaining an \"Outperform\" rating.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0077","symbol_name":"质押式回购","start_time":0,"source_url":"","article_id":"1101208731","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1101208731","pubTimestamp":1756719042,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Lyon released a research report stating that TIGERMED's (03347) second-quarter revenue declined 0.7% year-on-year to RMB 1.7 billion. New orders in the second quarter and July-August period both...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300347":"泰格医药","BK0077":"质押式回购","BK1576":"医药外包概念","BK1583":"高瓴概念","BK0028":"国家队","BK1141":"生命科学工具和服务","BK0216":"研究试验","BK0174":"增持","LU1146622755.USD":"安本中国A股股票基金A Acc","03347":"泰格医药","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H"},"translate_title":"里昂下调泰格医药目标价至58.9港元，下调盈利预测","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300347":1,"03347":1},"content_text":"Lyon released a research report stating that TIGERMED's (03347) second-quarter revenue declined 0.7% year-on-year to RMB 1.7 billion. New orders in the second quarter and July-August period both maintained double-digit growth, which aligns with the group's full-year order targets. The firm has reduced its revenue forecasts for TIGERMED for this year, next year, and 2027 by 6% across all periods, while earnings forecasts have been cut by 5% to 12%. The target price has been lowered from HK$62.6 to HK$58.9, while maintaining an \"Outperform\" rating.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}